U.S., Sept. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07192107) titled 'A Study of MHB042C in Patients With Advanced Solid Tumors' on Sept. 17.
Brief Summary: This is a first-in-human, open-label, multicenter Phase I/II study of MHB042C in patients with advanced solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of MHB042C monotherapy.
Study Start Date: Oct., 2025
Study Type: INTERVENTIONAL
Condition:
Advanced Malignant Solid Tumor
Intervention:
DRUG: MHB042C for Injection
IV administration of MHB042C Q2W or Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and con...